Characteristics of patients with recurrences
Patient | Recurrence site | Histology | G | FIGO stage | LSVI | Age (years) | LN status | Adjuvant treatment |
1 | Pelvic | Squamous | G2 | IB1 | – | 49 | +* | ChemoRT |
2 | Vaginal | Adenocarcinoma | G1 | IB1 | – | 39 | – | None |
3 | Vaginal | Adenocarcinoma | G1 | IB1 | – | 53 | – | None |
4 | Pelvic | Squamous | G1 | IB1 | + | 51 | – | Pre-op brachyth |
5 | Lung | Squamous | – | IB1 | – | 44 | – | None |
6 | Aortic LN | Squamous | G2 | IB1 | – | 69 | – | ChemoRT* |
7 | Vaginal | Squamous | – | IB1 | – | 58 | – | Pre-op brachyth |
8 | LN+lung | Squamous | – | IB1 | – | 52 | – | ChemoRT* |
9 | Vaginal+LN | Squamous | G3 | IB1† | + | 41 | – | ChemoRT |
10 | Sacrum | Squamous | G2 | IB1 | + | 74 | – | Pre-op brachyth |
11 | Pelvic | Squamous | G2 | IB1 | – | 35 | – | None |
12 | Pelvic | Squamous | – | IB1 | – | 56 | – | Pre-op brachyth |
13 | Pelvic | Squamous | – | IB1 | – | 64 | +** | None |
*Patients refused radical hysterectomy and so were treated with chemoradiotherapy.
†Parametrial involvement was demonstrated at the final pathology.
‡SLN positive for macrometastases.
§SLN positive for micrometastases.
ChemoRT, chemoradiotherapy;FIGO, International Federation of Gynecology and Obstetrics; G, grade;LN, lymph node;LVSI, lymph-vascular space involvement;SLN, sentinel lymph node; pre-op brachyth, pre-operative brachytherapy.